Mr. President, I remain concerned about the high levels of exposure Americans have to Bisphenol-A, BPA, an endocrine- disrupting chemical. BPA is a synthetic estrogen, which means that it mimics this hormone when in the body. Scientific studies continue to show cause for concern, especially for the health effects on babies, children, and expectant mothers. While these studies continue to examine the exact effects that BPA has on humans, consumers deserve more information. BPA is most commonly found in food products, such as the lining of canned goods like string beans, but consumers have no clear way of knowing this. The BPA in Food Packaging Right to Know Act is a simple solution to fix this problem. This legislation requires that food packaging that uses BPA include a clear label that reads, ``This food packaging contains BPA, an endocrine-disrupting chemical, according to the National Institutes of Health.'' This is basic information that consumers have the right to know so they can make informed decisions about the products they wish to purchase. This legislation also directs the Department of Health and Human Services to do a safety assessment of food containers that use BPA to determine if there is reasonable certainty that no harm will come from exposure, including from low doses over the long term.…
On the recordMarch 19, 2015
Source
govinfo.govShare & report
More from Dianne Feinstein
May 4, 2022
We urge the subcommittee to provide the following for the fiscal year 2023 Weatherization Assistance Program: the funding requested in the President's budget for the core program at no less than $362.2 million.
May 4, 2022
We hope your report will provide guidance to the Department of Energy regarding better integration of the program funded in this appropriation.
Nov 4, 2021
Mr. President, I rise today to speak in support of my bipartisan bill, the National Commission on the COVID-19 Pandemic Act. This bill would establish a 9/11-style Commission to conduct an investigation on the COVID-19 outbreak and…
May 4, 2022
We also urge the subcommittee to reject the proposed 'LIHEAP Advantage' $100 million project for reasons we outline below.





